Matrix Capital Management

Anumana develops AI algorithms that analyze ECG data to support early diagnosis of cardiovascular conditions. Its platform aims to enhance cardiac care by assisting healthcare professionals in identifying potential heart issues, improving patient outcomes throughout the continuum of cardiovascular care.

Rivos specializes in high-performance RISC-V systems, focusing on integrated solutions for enterprises. It manufactures computing chips designed to deliver efficient server systems for large language models and data analytics.

Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their complexity and difficulty in management. The company has developed a proprietary peptide-based platform designed to diagnose and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic, therapeutic, and anti-biofilm applications, particularly aimed at the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By focusing on early detection and effective treatment strategies, AltPep aims to enhance healthcare outcomes related to amyloid diseases, ultimately improving human health.

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

Acelyrin is a biopharmaceutical company dedicated to advancing treatments for diseases involving excessive immune system activation. It achieves this by discovering, acquiring, and expediting the development and market launch of innovative drug candidates.

Monod Bio is a life sciences company developing biosensors for detecting proteins, toxins, antibodies and other molecules. Its biosensor platform combines binding, transduction, and amplification in one step to detect a wide range of target molecules. The company leverages computational protein engineering to create modular bio-sensing nano switches that enable rapid, sensitive, and inexpensive analytical assays. Monod Bio was founded in 2021 and is headquartered in Seattle, Washington.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Founded in New York in 2018 by Anton Katz and Ethan Feldman, Talos is an institutional technology infrastructure provider that facilitates a comprehensive trading lifecycle for crypto ecosystem participants. It offers prime brokerage services, supporting spot, futures, and foreign exchange markets with institutional-grade technology.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

Blockdaemon facilitates blockchain deployment by offering a node management platform that supports over 30 protocols. It empowers businesses and developers to quickly launch and manage blockchain applications, with tools for exchanges, custodians, and financial institutions.

Founded in 2021, Solve Therapeutics is a biopharmaceutical company based in Belmont, California. It specializes in the development of first-in-class Antibody Drug Conjugates and Bispecific Therapeutics using its proprietary biotechnology platform.

Maze Therapeutics is a biotechnology company focused on developing medicines that mimic the effects of rare, protective genetic variants to address unmet medical needs. Utilizing its Compass platform, the company identifies genetic variants associated with diseases and maps them to the biological pathways driving these conditions in specific patient populations.

Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

Pramana, Inc. is a health technology company focused on transforming digital pathology for medical centers and pathology labs. It offers a comprehensive Digital Pathology as a Service (DPaaS) solution, which includes advanced whole slide imaging systems and a scalable software platform designed to enhance clinical workflows. By integrating the hardware capabilities acquired from Spectral Insights and the software expertise of nference, Pramana provides pathologists with access to AI-enabled decision support tools. This innovative approach allows medical professionals to obtain high-quality imaging while minimizing operational challenges, ultimately aiming to improve patient care on a global scale.

Acelyrin is a biopharmaceutical company dedicated to advancing treatments for diseases involving excessive immune system activation. It achieves this by discovering, acquiring, and expediting the development and market launch of innovative drug candidates.

Bardavon Health Innovations, LLC specializes in healthcare technology and services specifically designed for managing workers’ compensation cases. Established in 2013 and based in Overland Park, Kansas, the company offers a comprehensive approach to workers’ compensation, facilitating the management of the entire employee lifecycle, from hire to retirement. Its technology connects employers with essential tools and information, enabling informed decisions regarding employees in injury risk positions. Bardavon’s solutions enhance communication among therapy providers, referral sources, and other stakeholders, while simplifying reporting, data tracking, and job analysis. The company’s product offerings include bNOTES, bNOTES Connect, Telerehabilitation, Clinical Consulting, Job Analysis, Post-Offer Employment Testing, and XRTS Effort Assessment. By providing real-time updates on patient status and justifying the need for therapy treatment, Bardavon aims to empower quality healthcare decisions through improved transparency and collaboration.

Blockdaemon facilitates blockchain deployment by offering a node management platform that supports over 30 protocols. It empowers businesses and developers to quickly launch and manage blockchain applications, with tools for exchanges, custodians, and financial institutions.

GentiBio, Inc. is a biotherapeutics company that specializes in developing engineered regulatory T cells, known as EngTregs, aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, Washington, GentiBio employs a proprietary platform that combines autologous and allogeneic technologies. This platform enhances the ability to restore immune tolerance and addresses significant limitations found in existing regulatory T-cell therapeutics. By focusing on the underlying mechanisms of immune system disorders, GentiBio aims to provide innovative therapeutic solutions that tackle the root causes of diseases caused by dysregulated immune responses. The company is co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of advanced immunotherapy development.

Emboline develops innovative cardiovascular embolic protection devices for transcatheter and surgical cardiac procedures. Its flagship product, Emboliner, is an embolic protection catheter designed to safeguard cerebral arteries during percutaneous heart valve repair and replacement procedures.

Anumana develops AI algorithms that analyze ECG data to support early diagnosis of cardiovascular conditions. Its platform aims to enhance cardiac care by assisting healthcare professionals in identifying potential heart issues, improving patient outcomes throughout the continuum of cardiovascular care.

Anumana develops AI algorithms that analyze ECG data to support early diagnosis of cardiovascular conditions. Its platform aims to enhance cardiac care by assisting healthcare professionals in identifying potential heart issues, improving patient outcomes throughout the continuum of cardiovascular care.

Aura Biosciences is a clinical-stage biotechnology company founded in 2007 and based in Cambridge, Massachusetts. It develops cancer therapies using tumor-targeted pseudovirions, employing viral nanoparticles conjugated to infrared-activated molecules to selectively destroy cancer cells. The lead program AU-011 targets ocular melanoma, including primary choroidal melanoma, with the aim of treating tumors locally while reducing damage to surrounding tissue. The company pursues precision therapies for solid tumors and has ongoing development in other ocular oncology indications and bladder cancer, focusing operations in the United States.

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their complexity and difficulty in management. The company has developed a proprietary peptide-based platform designed to diagnose and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic, therapeutic, and anti-biofilm applications, particularly aimed at the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By focusing on early detection and effective treatment strategies, AltPep aims to enhance healthcare outcomes related to amyloid diseases, ultimately improving human health.

nference is a technology company that develops AI-based software platforms for transforming biomedical knowledge. It synthesizes structured and unstructured data from various sources, offering real-time insights through neural networks. The company provides services in drug discovery, lifecycle management, and precision medicine.

Palleon Pharmaceuticals is a biotechnology company developing drugs that target glycan-mediated immune regulation to treat cancer. Its platform integrates insights from glycoscience and human immunology, enabling it to create novel therapies targeting multiple immune cell types.

Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

nference is a technology company that develops AI-based software platforms for transforming biomedical knowledge. It synthesizes structured and unstructured data from various sources, offering real-time insights through neural networks. The company provides services in drug discovery, lifecycle management, and precision medicine.

Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

nference is a technology company that develops AI-based software platforms for transforming biomedical knowledge. It synthesizes structured and unstructured data from various sources, offering real-time insights through neural networks. The company provides services in drug discovery, lifecycle management, and precision medicine.

Qrativ Inc., established in 2017 and headquartered in Cambridge, Massachusetts, specializes in developing an AI-driven healthcare platform focused on identifying potential treatments for rare diseases. The company's core product is a drug purposing platform designed to revolutionize how therapies for unmet medical needs are discovered and developed. This platform, Darwin.ai, employs machine learning and artificial intelligence to uncover new uses for existing molecules, aiming to provide treatments for conditions where market-available drugs are lacking. Qrativ serves biotechnology and pharmaceutical companies with this innovative solution.

EpiBiome, Inc. is a precision microbiome engineering company based in South San Francisco, California, founded in 2013. The company is dedicated to developing therapies that address infectious diseases in humans and agriculture without relying on small-molecule antibiotics. EpiBiome focuses on phage therapy, which targets specific strains within the microbiome, effectively treating antibiotic-resistant infections. Its applications include treatment for mastitis in dairy cows and addressing infections caused by Escherichia coli in humans. By utilizing advanced sequencing and bioinformatic processes, EpiBiome aims to identify pathogenic bacteria and microbiome changes that contribute to disease, offering innovative alternatives to combat the rising threat of antibiotic resistance. As of July 2018, it operates as a subsidiary of Locus Biosciences, Inc.

nference is a technology company that develops AI-based software platforms for transforming biomedical knowledge. It synthesizes structured and unstructured data from various sources, offering real-time insights through neural networks. The company provides services in drug discovery, lifecycle management, and precision medicine.

Adaptive Biotechnologies Corporation is a commercial-stage company focused on advancing immune-driven medicine by leveraging the biology of the adaptive immune system to enhance disease diagnosis and treatment. Established in 2009 and headquartered in Seattle, Washington, the company offers a range of products and services, including its FDA-authorized clonoSEQ diagnostic test, which is designed for the detection and monitoring of minimal residual disease in patients with specific blood cancers, such as multiple myeloma and chronic lymphocytic leukemia. In addition to clonoSEQ, Adaptive Biotechnologies provides immunoSEQ research services and kits to support scientific research and the discovery of new diagnostic signals. The company also has a pipeline of clinical products aimed at diagnosing and managing various diseases, including cancers, autoimmune disorders, and infectious diseases. It maintains strategic collaborations with notable partners such as Genentech and Microsoft to develop innovative therapies and diagnostic tests.

Xero Limited is a New Zealand-based technology company that specializes in cloud-based accounting software designed for small and midsize enterprises, as well as accounting practices. Founded in 2006 and headquartered in Wellington, Xero offers a comprehensive suite of tools, including its core accounting software, a mobile app, and various solutions for accountants and bookkeepers, such as Xero HQ and Xero Practice Manager. The platform enables users to efficiently manage cash flow, invoicing, payments, and reporting through a subscription model with three tiers: starter, standard, and premium. Xero has established a strong market presence in New Zealand and Australia, successfully competing against traditional accounting software providers, and has expanded its services to other English-speaking countries, particularly the United Kingdom.

Xero Limited is a New Zealand-based technology company that specializes in cloud-based accounting software designed for small and midsize enterprises, as well as accounting practices. Founded in 2006 and headquartered in Wellington, Xero offers a comprehensive suite of tools, including its core accounting software, a mobile app, and various solutions for accountants and bookkeepers, such as Xero HQ and Xero Practice Manager. The platform enables users to efficiently manage cash flow, invoicing, payments, and reporting through a subscription model with three tiers: starter, standard, and premium. Xero has established a strong market presence in New Zealand and Australia, successfully competing against traditional accounting software providers, and has expanded its services to other English-speaking countries, particularly the United Kingdom.

Xero Limited is a New Zealand-based technology company that specializes in cloud-based accounting software designed for small and midsize enterprises, as well as accounting practices. Founded in 2006 and headquartered in Wellington, Xero offers a comprehensive suite of tools, including its core accounting software, a mobile app, and various solutions for accountants and bookkeepers, such as Xero HQ and Xero Practice Manager. The platform enables users to efficiently manage cash flow, invoicing, payments, and reporting through a subscription model with three tiers: starter, standard, and premium. Xero has established a strong market presence in New Zealand and Australia, successfully competing against traditional accounting software providers, and has expanded its services to other English-speaking countries, particularly the United Kingdom.

Tenor Networks, Inc. is a company that specializes in the development and manufacturing of optical switching systems. The firm offers products such as the TN250G, a Core MPLS Switch, and TEMPo, an element management platform designed for managing optical networks. In addition to its hardware, Tenor Networks provides service intelligence solutions that enhance the performance and efficiency of communication networks. The company's focus on advanced optical technologies positions it as a key player in the telecommunications equipment market.